Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620675 | 0.85 | KDM4C (0.54) | KDM4CKMT2AMEN1NPC1RAB9A | |
| SCHEMBL18569601 | 0.83 | MEN1 (0.46) | KMT2AMEN1NPC1POLB | |
| SCHEMBL16220648 | 0.81 | KMT2A (0.61) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL14904964 | 0.80 | KMT2A (0.52) | KDM4CKMT2AMEN1NPC1RAB9A | |
| SCHEMBL3504843 | 0.80 | MAOB (0.63) | KDM4CKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6072144 | 0.80 | L3MBTL1 (0.55) | KDM4CKMT2AMEN1NPC1RAB9A | |
| SCHEMBL27983390 | 0.80 | KDM4C (0.51) | KDM4CKMT2AMEN1NPC1RAB9A | |
| SCHEMBL10710100 | 0.80 | KDM4C (0.55) | KDM4CKMT2AMEN1NPC1RAB9A | |
| SCHEMBL620468 | 0.79 | KDM4C (0.55) | KDM4CKMT2AMEN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL10710861 | 0.78 | MAOB (0.61) | KDM4CKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9303029-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9303029-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| WO-2013061081-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | KDM4C 1139/4885PYGL 535/4885KMT2A 691/4885 |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR4, FGFR3 | KDM4C 731/4885PYGL 1350/4885KMT2A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.